Pipeline Report 2025: Late-stage programs set to reshape treatment
Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.
Background: CELMoDs (cereblon E3 ligase modulators) are oral small molecules that bind cereblon to trigger degradation of key myeloma survival proteins, directly inducing tumor-cell apoptosis. They build on the older immunomodulatory drugs (IMiDs).
- Iberdomide RRMM (EXCALIBER-RRMM) and mezigdomide RRMM (SUCCESSOR 1 and 2) registrational data are expected in late 2025 and early 2026.
- Peak sales predictions for the combination are approximately $5 billion by 2032.
After lingering in the BMS pipeline since the infamous $74 billion Celgene acquisition in 2019 and overshadowed by high-profile cell therapies, they’re now nearing center stage with pivotal data imminent.
These CELMoDs will be used alongside standard myeloma backbone combinations and across multiple settings representing a large market opportunity.
Author's summary: CELMoDs are approaching critical development stage.